COMPANY PRESS RELEASE: BEA System one of the world’s leading e-business infrastructure software companies has announced that it has won a contract with the Discovery Information Systems division of AstraZeneca, one of the world’s leading pharmaceutical companies.
BEA WebLogic Server was selected to provide the company with an open platform for application delivery.
Having taken advice from industry analysts, we reviewed a broad range of solutions, said Neil Chadwick, technical architect and application server component manager for AstraZeneca Discovery IS. When compared to alternative application servers, BEA WebLogic Server was clearly the most appropriate solution for our business.
The management of research data is one of the biggest issues for IT departments across the pharmaceutical industry. The amount of data doubles every nine months. Researchers are required to search manually for information across numerous sources within the organization or replicate tests already completed but stored in remote locations.
BEA WebLogic Server will form part of the platform to integrate research data from across AstraZeneca Discovery’s 10 global sites, enabling the data to be accessible to anyone who needs it. This will allow, for example, a person in Canada to access data from tests done in Sweden. AstraZeneca will provide a variety of tools for further analyzing and manipulating that data.
The increase in productivity in drug research should result in a significant reduction in drug development costs for AstraZeneca and a significant improvement in new leads. Each day a potential drug is not on the market can cost a pharmaceutical company millions of dollars in lost sales. The speed with which Discovery will be able to share information across the world should improve the quality of decision-making, prevent duplication and reduce development time and cost.
BEA is at the forefront of J2EE technologies, implements new standards quickly, is well supported by third-party vendors and should enable new applications to be integrated much faster than other offerings, Chadwick said. J2EE is a new route for us from our traditional client server model, but it is clearly the path we need to take for scalable, reliable global solutions. BEA WebLogic gives us greater integration ability, thus reducing project costs essential in an increasingly competitive market such as ours.
Approximately 3,500 Discovery users will eventually have access to applications based on the BEA WebLogic Server technology. Sites in Sweden, the United States and the UK will go live first. AstraZeneca expects the application to be live across all sites over the next five years. Two platforms will be hosting the BEA WebLogic Server a primary Sun Solaris platform for non-regulated systems and a Windows 2000 platform for regulated systems. Both platforms will also support Oracle and a variety of specialised Discovery tools.